ALK and non-small cell lung carcinoma: Particularly in advanced Non-Small Cell Lung Cancer (NSCLC), treatment options have evolved with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK)- and ROS proto-oncogene 1 (ROS1) directed treatment [1,2,3].